Fc-modified anti-CD40L mAb

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers

Staff Reporter February 28, 2024 0

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced...

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers

Boston Scientific Launches AVVIGO™+ Multi-Modality Guidance System in India

KW Delhi-6 Mall Joined Hands with Yashoda Healthcare to Spread Awareness on Breast Cancer

India’s reputation as the “Pharmacy to the World” is Potentially Under Threat Substandard Imports of IPA add to the Quality Burden

Sculpt Clinics Introduces New Laser Hair Removal Technology

HEAL Foundation Announces Healthcare CSR Summit & Awards in New Delhi

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers￼

Interesting Stories For You

Boston Scientific Launches AVVIGO™+ Multi-Modality Guidance System in India

KW Delhi-6 Mall Joined Hands with Yashoda Healthcare to Spread Awareness on Breast Cancer

India’s reputation as the “Pharmacy to the World” is Potentially Under Threat Substandard Imports of IPA add to the Quality Burden

Sculpt Clinics Introduces New Laser Hair Removal Technology

HEAL Foundation Announces Healthcare CSR Summit & Awards in New Delhi

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers